PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD8186. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

23 hits

Bibliografisk träff 2025-04-15

Identification of disulfidptosis in esophageal squamous cell carcinoma based on single-cell and bulk RNA-seq data to predict prognosis and treatment response.

Zhang X, Du J, Lin X, Zhang S, Zeng T, Chen M, Huang G, Chen C, Zheng B.

Front Immunol · research-article; journal article · DOI 10.3389/fimmu.2025.1567793

Bibliografisk träff 2025-03-27

Molecular mechanisms and therapeutic targets in glioblastoma multiforme: network and single-cell analyses.

Chen X, Zhong X, Zhang F, Zhou X, Yue X, Li X.

Sci Rep · research-article; journal article · DOI 10.1038/s41598-025-92867-z

Bibliografisk träff 2025-03-20

A novel bone metastasis-related gene signature for predicting prognosis, anti-androgen resistance, and drug choice in prostate cancer.

Luo Y, Deng X, Wei C, Liu Z, Song L, Han K, Li Y, Zhang J, Su S, Wang D.

J Bone Oncol · research-article; journal article · DOI 10.1016/j.jbo.2025.100673

Bibliografisk träff 2025-02-28

Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition.

Ling S, Dexter A, Race AM, Sharma S, Hamm G, Polanska UM, Rosetta Consortium Cancer Research UK, Marshall JF, Takats Z, Brindle K, Yuneva MO, Poulogiannis G, Campbell AD, Sansom OJ, Goodwin RJA, Bunch J, Barry ST.

Dis Model Mech · research-article; journal article · DOI 10.1242/dmm.050804

Bibliografisk träff 2024-12-18

Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.

Zhao J, Zhang Q, Zhu C, Yuqi W, Zhang G, Wang Q, Dong X, Li B, Wang X.

BioData Min · research-article; journal article · DOI 10.1186/s13040-024-00377-x

Bibliografisk träff 2024-04-01

Correction to: AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).

Författaruppgift saknas

Oncologist · published erratum; correction · DOI 10.1093/oncolo/oyad287

Bibliografisk träff 2024-01-28

β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models.

Korovina I, Elser M, Borodins O, Seifert M, Willers H, Cordes N.

Biomed Pharmacother · research-article; journal article · DOI 10.1016/j.biopha.2024.116217

Bibliografisk träff 2024-01-22

Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.

Ruiz de Porras V, Bernat-Peguera A, Alcon C, Laguia F, Fernández-Saorin M, Jiménez N, Senan-Salinas A, Solé-Blanch C, Feu A, Marín-Aguilera M, Pardo JC, Ochoa-de-Olza M, Montero J, Mellado B, Font A.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2024.1331648

Bibliografisk träff 2023-09-01

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).

Suh KJ, Ryu MH, Zang DY, Bae WK, Lee HS, Oh HJ, Kang M, Kim JW, Kim BJ, Mortimer PGS, Kim HJ, Lee KW.

Oncologist · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1093/oncolo/oyad059

Bibliografisk träff 2022-11-09

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.

Xu W, Berning P, Erdmann T, Grau M, Bettazová N, Zapukhlyak M, Frontzek F, Kosnopfel C, Lenz P, Grondine M, Willis B, Lynch JT, Klener P, Hailfinger S, Barry ST, Lenz G.

Leukemia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41375-022-01749-0

Bibliografisk träff 2022-10-14

Untargeted stable isotope-resolved metabolomics to assess the effect of PI3Kβ inhibition on metabolic pathway activities in a PTEN null breast cancer cell line.

Lackner M, Neef SK, Winter S, Beer-Hammer S, Nürnberg B, Schwab M, Hofmann U, Haag M.

Front Mol Biosci · research-article; journal article · DOI 10.3389/fmolb.2022.1004602

Bibliografisk träff 2022-06-01

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.

Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR.

Clin Cancer Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-21-3087

Bibliografisk träff 2020-03-17

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.

Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.27503

Bibliografisk träff 2020-03-03

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.

Wu YH, Huang YF, Chen CC, Huang CY, Chou CY.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.00206

Bibliografisk träff 2020-01-07

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.

Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-19-1633

Bibliografisk träff 2019-01-18

<i>SETD2</i> loss sensitizes cells to PI3Kβ and AKT inhibition.

Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.26567

Bibliografisk träff 2018-08-10

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.

Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A, Cumberbatch M, Klinowska T, Critchlow SE, Cruzalegui F, Barry ST.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-18-0183

Bibliografisk träff 2018-07-02

A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.

Wang XS, Ding XZ, Li XC, He Y, Kong DJ, Zhang L, Hu XC, Yang JQ, Zhao MQ, Gao SG, Lin TY, Li Y.

Nanomedicine · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.nano.2018.06.008

Bibliografisk träff 2017-10-02

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.

Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-17-0676

Bibliografisk träff 2016-08-11

The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.

Maynard J, Emmas SA, Blé FX, Barjat H, Lawrie E, Hancox U, Oakes D, Polanska UM, Barry ST.

EJNMMI Res · research-article; journal article · DOI 10.1186/s13550-016-0220-9

Bibliografisk träff 2015-01-07

Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Pasquet MJ, Péru A, Plé P, Saleh T, Vautier M, Walker M, Ward L, Warin N.

J Med Chem · journal article · DOI 10.1021/jm501629p

Bibliografisk träff 2014-12-24

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccell.2014.11.008

Bibliografisk träff 2014-11-14

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-14-0406